NY-IFF
4.6.2019 16:02:08 CEST | Business Wire | Press release
Regulatory News:
IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, has been breaking boundaries since its beginning in 1889. Today, IFF is kicking off a new era that celebrates its history of innovation, customer-centric focus, new capabilities and the drive to deliver for customers of any size. IFF’s new purpose: To redefine & transform how we live in and care for the resources of our world, shows its commitment to being more than a flavors and fragrances company – it advances its promise to do better for people and planet – and in doing so, supporting its customers in their efforts to do the same. A new brand identity and mantra of Uncommon Sense encourages customers and employees alike to reject convention in favor of delivering what the world needs.
Andreas Fibig, IFF Chairman and CEO, says that the new brand is designed to challenge expectations: “Five years ago, we promised to redefine IFF’s role in the flavors and fragrances industry. Since that time, we have nearly doubled our product offerings, sales and world-class talent and expanded our customers base by more than tenfold. We have become a leader in sustainability -- responsible for many industry firsts – and galvanized our employees to embrace their role in making the world a better place.”
Mr. Fibig continued, “With such a diverse and expansive organization, we needed a purpose that can connect us globally. So, we’ve created something new in our industry – a purpose that both embraces and goes beyond our day-to-day and helps us reach higher for the good of people and our planet. That’s the essence of who we are. We want to be ahead, doing more and doing it better than the rest. Our new purpose and Uncommon Sense brand are aiming high, but I believe our purpose should bring our people together while making us stretch beyond what we think is possible today.”
Uncommon Sense, the Company’s new mantra, challenges its employees to rethink conventional wisdom to create a culture where ideas and possibilities flow. Mr. Fibig said, “This is the type of approach that has led to some of the biggest dreams and greatest inventions of our world. These are the ideas that have allowed us to fly, that have sent humans to the moon; that let us dream of living on Mars. Uncommon Sense opens the door for us to make the impossible, possible.”
The brand is underpinned by three pillars: Question Everything, Champion Creators, and Do More Good. Unapologetically bold and purposefully inclusive, the new identity expands the definition of IFF’s work and reaches further than ever before. To learn more about IFF’s next era, watch the new brand video at www.iff.com .
# # #
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005643/en/
Contact:
IFF Michael DeVeau Head of Investor Relations and Communications & Divisional CFO, Scent 212.708.7164 Michael.DeVeau@iff.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release
AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr
IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 22:24:00 CET | Press release
The demonstrator being built in this project delivers a clear path toward scalable and fault-tolerant quantum computers. The joint project integrates IQM’s superconducting quantum processor, Zurich Instruments’ ZQCS Quantum Control System, with the NVIDIA NVQLink platform to enable real-time error correction. This initiative establishes a foundation for standardized enterprise-ready quantum systems, and datacenter deployment. Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
